| miR-214 is a tumor-suppressor of human hepatocellular carcinoma (HCC). Its downregulation is associated with worse prognosis. miR-214 downregulation contributes to hypervascularity of HCC via the induction and secretion of hepatoma-derived growth factor. | liver, |
| These findings indicate that miR-214 serves as tumor suppressor and plays substantial roles in inhibiting the tumorigenesis of hepatocellular carcinoma through suppression of beta-catenin. | liver, |
| our data indicate that miR-214 may function as tumor suppressor in glioma by targeting PCBP2 | glioma, |
| miR-214 and miR-218 function as tumor suppressors in breast cancer, and may become biomarkers and potential therapeutic targets in breast cancer. | breast, |
| The data indicate that in the context of hepatocellular carcinoma, miR-214 acts as a putative tumour suppressor by targeting UCP2 and defines a novel mechanism of regulation of UCP2. | liver, |
| In conclusion, miR-214 functions as a tumor suppressor by regulating the RFWD2-p53 cascade, thus delivery of miR-214 analogs could be a potential adjunct therapy in breast cancer harboring wild type p53. | liver,breast, |
| In conclusion, our study revealed that miR-214 acts as a tumor suppressor via inhibiting proliferation, migration and invasion of cervical cancer cells through targeting ARL2, and that both miR-214 and ARL2 may serve as prognostic or therapeutic targets for cervical cancer. | cervical, |
| miR-214 expression exhibited a frequent down-regulation in human esophageal squamous cell carcinoma (ESCC) tissues and cells, compared to adjacent normal tissues and cells; our results indicate that miR-214 function as a tumor suppressor in ESCC | esophageal, |
| The overexpression of miR-214 in ovarian cancer cell lines led to the G0/G1 phase arrest and expression of beta-catenin, Cyclin D1, and c-Myc was suppressed. MiR-214 may serve as a tumor suppressor of ovarian cancer by targeting the beta-catenin pathway. | ovarian, |
| the miR-214-RNF8 axis has a role in epithelial-mesenchymal transition in breast cancer; miR-214 acts as a tumor suppressor | breast, |
| miR-214-5p was identified as a new tumor suppressor, which directly targeted ROCK1 and suppressed proliferation of human OS cells. | None |
| miR-214 functions as a tumor suppressor in PTC cells by targeting PSMD10, suggesting that it may be a potential target for the treatment of PTC. | None |
| MiR214 mimics upregulated the expression of hypoxiainducible factor (HIF)1alpha, vascular endothelial growth factor (VEGF), adenylate kinase 3 and matrix metalloproteinase (MMP)2, whereas miR214 inhibitor downregulated the expression of these factors. Using prediction software, it was demonstrated that tumor suppressor ING4 was a target of miR214. | None |
| miR-214 functions as an onco-miRNA in osteosarcoma, and its oncogenic effects are mediated chiefly through downregulation of LZTS1 | osteosarcoma, |
| miR-214 functions as an oncogene in BC, at least partly by promoting cell invasion through the downregulation of p53. | None |
| these findings suggest that miR214 possesses oncogenic activity and that its effects are mediated through the promotion of cell growth by targeting the PTENPI3K/Akt pathway. | None |